1Schiff R, Maasarweh S, Shou J, et al. Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate respond. Clin Cancer Res, 2003, 9 ( Pt2 ) : 447s-454s.
2Iwase H, Zhaatg Z, Ornoto Y, et al. Clinical significance of the expression of estrogen receptors alpha and beta for endocrine therapy of breast cancer. Cancer Chemother Pharmacol, 2003, 52 ( Suppll ) :S34-38.
3Hayashi SI, Eguchi H, Tanimoto K, et al. The expression and function of estrogen receptor alpha and beta in human breast cancer and its clinical application. Endocr Relat Cancer, 2003, 10(2) : 193-202.
4Liu Z, Auboeuf D, Wong J et al. Coactivator/corepressor ratios modulate PR-mediated transcription by the elective receptor modulator RU486. Proc Natl Acad Sci USA, 2002,99(12) : 7940-7944.
5Graham JD. Pain DL, Richer JK, et al. Thoughts on tamoxifen resistant breast cancer. Are coregulators the answer or just a red herring? J Steroid Biochem Mol Biol, 2000,74(5) : 255-259.
6Wu RC, Qin J, Hashimoto Y, et al. Regulation of SRC-3 (pCIP/ACFR/AIB-1/RAC-3/TIUMM-1) coactivator activity by I kappa B kinase. Mol Cell Biol, 2002,22(10): 3549-3561.
7McKenna N J, O' Malley BW. From ligand to respond: generating diversity in nuclear receptor coregulator function. J Steroid Biochem Mol Biol, 2000,74(5): 351-356.
8Ko L, Cardona GR, Iwasaki T, et al. Ser-884 adjacent to the LXXLL motif of coactivator 453S Clinical Cancer Research TRBP defines selectivity for ERs and TRs. Mol Endocrinol, 2002,16( 1 ) :128-140.
9Shang Y, Brown M. Molecular determinants for the tissue specificity of SERMs. Science, 2002,295(5564) : 2465-2468.
10Hudelist G, Czerwenka K, Kubista E, et al. Expression of sex steroid receptor and their co-factors in normal and malignam breast tissue: AIBI is a carcinoma-specific coactivator. Breast Cancer Res Treat, 2003,78(2) : 193-204.
8Sararto T, Blomqvist C, Ehnholm C et al . Antiatherogeme effects of adjuvant antiestrogens; a randomized trial comparing the effects of tamoxifen and toremifene on plasma lipid levels in postmenopausal women with no-de-positive breast cancer. J Clin Oncol, 1996,14:429.
9Butmell Charles A, Hendriksen Barry A, Larsen Samuel D. Framleithsla og kristalform af 2 - methyl - thteno - bensodiasepin. US Patent, IS4446,1997.01.
10Gradishar W, Glusman J, Lu Yet al . Effects of highdose raloxifene in selected patients with advancedbreast carcinoma. Cancer, 2000, 88 (9) :2 047.
